RhumbLine Advisers’s Impax Laboratories, Inc. IPXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-179,946
| Closed | -$3.5M | – | 2987 |
|
|
2018
Q1 | $3.5M | Buy |
179,946
+2,865
| +2% | +$56.2K | 0.01% | 1279 |
|
|
2017
Q4 | $2.95M | Buy |
177,081
+21,775
| +14% | +$399K | 0.01% | 1397 |
|
|
2017
Q3 | $3.15M | Buy |
155,306
+2,589
| +2% | +$49.5K | 0.01% | 1320 |
|
|
2017
Q2 | $2.46M | Buy |
152,717
+7,393
| +5% | +$109K | 0.01% | 1451 |
|
|
2017
Q1 | $1.84M | Buy |
145,324
+38,227
| +36% | +$462K | ﹤0.01% | 1603 |
|
|
2016
Q4 | $1.42M | Buy |
107,097
+5,172
| +5% | +$88.4K | ﹤0.01% | 1643 |
|
|
2016
Q3 | $2.42M | Buy |
101,925
+6,395
| +7% | +$172K | 0.01% | 1286 |
|
|
2016
Q2 | $2.75M | Buy |
95,530
+3,184
| +3% | +$104K | 0.01% | 1159 |
|
|
2016
Q1 | $2.96M | Buy |
92,346
+2,715
| +3% | +$95.4K | 0.01% | 1127 |
|
|
2015
Q4 | $3.83M | Sell |
89,631
-370
| -0.4% | -$14.8K | 0.01% | 952 |
|
|
2015
Q3 | $3.17M | Buy |
90,001
+3,535
| +4% | +$159K | 0.01% | 1064 |
|
|
2015
Q2 | $3.97M | Sell |
86,466
-22,440
| -21% | -$1.07M | 0.01% | 978 |
|
|
2015
Q1 | $5.1M | Buy |
108,906
+2,800
| +3% | +$111K | 0.01% | 830 |
|
|
2014
Q4 | $3.36M | Buy |
106,106
+2,654
| +3% | +$77.7K | 0.01% | 1025 |
|
|
2014
Q3 | $2.45M | Sell |
103,452
-1,020
| -1% | -$26.1K | 0.01% | 1189 |
|
|
2014
Q2 | $3.13M | Sell |
104,472
-5,436
| -5% | -$147K | 0.01% | 1082 |
|
|
2014
Q1 | $2.9M | Sell |
109,908
-3,475
| -3% | -$86.8K | 0.01% | 1121 |
|
|
2013
Q4 | $2.85M | Sell |
113,383
-6,320
| -5% | -$141K | 0.01% | 1146 |
|
|
2013
Q3 | $2.46M | Buy |
119,703
+5,303
| +5% | +$110K | 0.01% | 1214 |
|
|
2013
Q2 | $2.28M | Buy |
+114,400
| New | +$2.03M | 0.01% | 1215 |
|
RhumbLine Advisers's IPXL Position: Q2 2018 in Review
RhumbLine Advisers sold out of Impax Laboratories, Inc. (IPXL) in Q2 2018, closing a stake of 179,946 shares — an estimated $3.5M sold.
RhumbLine Advisers first reported a position in IPXL in Q2 2013 and held it in 20 quarters. The position peaked at $5.1M in Q1 2015. 1 fund tracked by Wall St. Rank holds IPXL as of Q2 2018.
- RhumbLine Advisers reported no remaining Impax Laboratories, Inc. position as of Q2 2018 after selling out during the quarter.
- RhumbLine Advisers sold 179,946 Impax Laboratories, Inc. shares in Q2 2018, an estimated $3.5M.
- RhumbLine Advisers first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 20 quarters.
- RhumbLine Advisers's Impax Laboratories, Inc. position peaked at $5.1M in Q1 2015.
- 1 fund tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2018.
Based on RhumbLine Advisers's 13F filing for Q2 2018, filed 6 Aug 2018.